Upstream Bio, Inc. (UPB): A Bull Case Theory 

We came across a bullish thesis on Upstream Bio, Inc. on Value investing subreddit by Dizzy_Drawing_2451. In this article, we will summarize the bulls’ thesis on UPB. Upstream Bio, Inc.’s share was trading at $19.97 as of September 5th.

Countries with the Highest Cancer Rates in the World in 2018

Photographee.eu/Shutterstock.com

Upstream Bios (UPB) is developing Verekitug, a long-acting TSLP receptor-targeted biologic that could reshape treatment in chronic respiratory diseases, including severe asthma, chronic rhinosinusitis with nasal polyps...